Secondary Logo

Journal Logo

Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection

Gao, Nana,†; Wang, Weib,c,†; Wang, Chua,†; Gu, Tiejuna,d; Guo, Ruia; Yu, Bina,d; Kong, Weia,d; Qin, Chuanb,c; Giorgi, Elena, E.e; Chen, Zhiweif; Townsley, Samanthag; Hu, Shiu-Lokg; Yu, Xianghuia,d,*; Gao, Fenga,h,*

doi: 10.1097/QAD.0000000000001724
BASIC SCIENCE
Free
SDC

Objective: Nonhuman primates (NHPs) are the only animal model that can be used to evaluate protection efficacy of HIV-1 envelope vaccines. However, whether broadly neutralizing antibodies (bnAbs) can be elicited in NHPs infected with simian/human immunodeficiency virus (SHIV) has not been fully understood. The objective of this study is to investigate whether broad neutralization activities were developed in SHIV-infected macaques after long-term infection as in humans.

Design: Neutralization breadth and specificities in plasmas from SHIV-infected macaques were determined by analyzing a panel of tier 2 viruses and their mutants.

Methods: Forty-four Chinese macaques infected with SHIV1157ipd3N4, SHIVSF162P3 or SHIVCHN19P4 were followed for 54–321 weeks. Archived plasmas from 19 macaques were used to determine neutralization breadth and specificities against 17 tier 2 envelope-pseudoviruses.

Results: Longitudinal plasma from three SHIVSF162P3-infected macaques and three SHIV1157ipd3N4-infected macaques rarely neutralized viruses (<25%) within 1 year of infection. The neutralization breadth in two SHIV1157ipd3N4-infected macaques significantly increased (≥65%) by year 6. Four of six SHIV1157ipd3N4-infected macaques could neutralize 50–75% viruses, whereas none of macaques infected with SHIVSF162P3 or SHIVCHN19P4 could neutralize more than 25% of viruses after 6 years of infection (P = 0.035). Neutralization specificity analysis showed mutations resistant to bnAbs in V2, V3 or CD4bs regions could abrogate neutralization by year-6 plasma from three SHIV1157ipd3N4-infected macaques.

Conclusion: These results demonstrate that bnAbs targeting common HIV-1 epitopes can be elicited in SHIV1157ipd3N4-infected macaques as in humans after 4–6 years of infection, and SHIV/NHP can serve as an ideal model to study bnAb maturation.

aNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin

bInstitute of Laboratory Animal Science, Chinese Academy of Medical Sciences

cComparative Medicine Center, Peking Union Medical College, Beijing

dKey Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences, Jilin University, Changchun, Jilin, China

eTheoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico, USA

fAIDS Institute and Department of Microbiology, Research Centre for Infection and Immunity, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pok Fu Lam, Hong Kong Special Administrative Region

gDepartment of Pharmaceutics, University of Washington, Seattle, Washington

hDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, USA.

Correspondence to Feng Gao, Duke University, Durham, North Carolina, USA. E-mail: fgao@duke.edu

Received 18 September, 2017

Revised 25 October, 2017

Accepted 2 November, 2017

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

Back to Top | Article Outline

Introduction

An effective HIV-1 vaccine will most likely require the ability to induce broadly neutralizing antibodies (bnAbs) against diverse globally circulating HIV-1 strains. During natural HIV-1 infection, about 20% of HIV-1-infected individuals develop neutralization activity with significant breadth after 3–5 years of infection [1–5]. A large number of bnAbs targeting five major conserved epitopes on HIV-1 envelope glycoprotein have been identified from a small number of HIV-1-infected individuals and have been fully characterized for their crystal structures and target epitopes [6,7]. Infusion of bnAbs can protect repeated simian/human immunodeficiency virus (SHIV) challenges in macaques [8] and HIV-1 challenges in humanized mice [9,10]. These results raise the hope that bnAbs can protect acquisition of infection if they are elicited by vaccination. Although no vaccines have been able to elicit bnAbs in humans or nonhuman primates (NHPs), nAbs neutralizing autologous tier 2 viruses could be detected in NHPs [11,12] and increased neutralization breadth was induced by the germline targeting approach in which the reverted bnAb germline was knocked in mice [13].

The only animal model to evaluate protection efficacy of a nAb-based vaccine is NHP by challenging with SHIVs, in which the env gene from the simian immunodeficiency virus (SIV) is replaced by the env gene from HIV-1. SHIV-infected NHPs are generally not maintained more than 2–3 years after infection when planned experiments are accomplished. As broad neutralization activity is generally detected after 3–5 years of infection in humans [14–17], bnAbs do not have enough time to develop in those macaques. This may explain why only a few macaques were found to have relatively broad neutralization activity within 1–2 years of infection [18–21]. In this study, we have followed macaques infected with different SHIVs for up to 6 years and found broad neutralization activities in two macaques after 5–6 years of infection. Furthermore, their neutralization specificities (CD4bs, V3 and V2) were similar to those found in HIV-1 infected humans. More detailed characterization of bnAbs in those macaques will be highly informative for vaccine design to elicit broadly reactive vaccines and appropriacy of the SHIV/NHP model to evaluate bnAb-based vaccines.

Back to Top | Article Outline

Methods

Simian/human immunodeficiency virus infection in nonhuman primate

Chinese rhesus (Rh) macaques were challenged with SHIV1157ipd3N4[22], SHIVSF162P3[23] or SHIVCHN19P4[24] intravenously at various doses (5–500 TCID50) or at multiple low-dose method intrarectally up to 10 times (10–50 TCID50). Persistent infection was determined by measuring viral loads in plasma using a quantitative real-time-PCR as previously described [25]. All macaques were cared for in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Science and with the recommendations of the Weatherall report (the use of NHPs in research). All animals tested negative for simian type D retroviruses, simian T-cell leukemia virus-1, and SIV before the start of each study.

Back to Top | Article Outline

Neutralization assay

Neutralizing titers of plasmas were assessed by single-round infection of TZM-bl with envelope (Env) pseudoviruses as described previously [26]. Briefly, inactivated plasma samples were prepared at three-fold serial dilutions starting at 1 : 30. The diluted samples were incubated with Env pseudoviruses (100 TCID50) for 1 h at 37 °C and then used to infect TZM-bl cells. The luciferase activity was measured after 48 h. The definition of 50% inhibitory dose (ID50) reported as plasma reciprocal dilution was the sample dilution at which relative luminescence units (RLU) were reduced by 50% compared with RLU in virus control wells after subtraction of background RLU in cell control wells. A response was considered positive for neutralization if the ID50 titer was more than 1 : 30.

Back to Top | Article Outline

Neutralization specificity analysis

Mutations that affect bnAb binding to V2 (N160K), V3 (N332A) and CD4bs (N279A, N280D and V295N) regions were introduced into the Ce1176 env clone using the QuikChange mutagenesis kit (Stratagene, La Jolla, California, USA). The identity of all mutants was confirmed by sequencing and the neutralization susceptibility of pseudotyped viruses bearing mutant Env was confirmed by TZM-bl assay against a panel of bnAbs as previously described [27]. CAP45.2.00.G3 env mutants containing mutations at V2 (N160A, T162A, R166A, D167N, K169V and K169E), CD4bs (T236K and N276D) and gp41 (N616A, N637A and N674A) regions were generated from a previous study [28]. Pseudoviruses were produced by transfection of 293T cells with an env-deficient genomic back-bone plasmid (pSG3ΔEnv) and each env mutant. Potential epitopes were determined by resistance of mutants to plasma from G1015R or G1020R collected at week 321.

Back to Top | Article Outline

Statistical analysis

To test whether breadth and potency of the neutralization responses increased over time, we used a mixed-effect generalized linear model (GLM) with the neutralization data as dependent variable (both magnitude and breadth), SHIV stains and time as independent variables, as well as Envs and animals as random effects. We tested for possible interactions between all independent variables, and then, in a separate model, we used all independent variables additively and then stepwise removed nonsignificant variables until we found the best predictive model. All analyses were performed in R [29] using the lme4 package [30] and all P values were obtained through the analysis of variance chi-square test.

Back to Top | Article Outline

Results

Persistent simian/human immunodeficiency virus infection in Chinese rhesus macaques

Previous studies showed that susceptibility to SIV infection and death rates were lower in Chinese Rh macaques compared with Indian Rh macaques [31,32]. To determine if SHIV can also establish long-term infection with relatively high viral loads, which are generally required for inducing bnAbs in NHPs [33] and humans [34,35], we studied the persistent infection among 40 SHIV-infected macaques established from our previous study [25]. Twenty macaques were infected with SHIVSF162P3 and the other 20 macaques were infected with SHIV1157ipd3N4. Each virus was given intravenously or intrarectally at various doses. Nine intravenously infected macaques did not establish infection due to low doses. Among 31 infected macaques, 15 were infected with SHIVSF162P3 (10 intrarectal infection and five intravenous infection), whereas 16 were infected with SHIV1157ipd3N4 (10 intrarectal infection and six intravenous infection) (Fig. 1). All infected macaques had high peak viremia during the acute infection stage. Viral loads decreased to the baseline around 30 weeks after infection, but rebounded to various levels after 1 year of infection. Viral loads were measured every 1 or 2 years during the next 170 weeks. Throughout the follow-up period, no macaques died of AIDS-related symptoms. All monkeys were euthanized at week 217 except G1015R and G1020R (infected with SHIV1157ipd3N4), which maintained high viral loads for next 104 weeks.

Fig. 1

Fig. 1

Back to Top | Article Outline

Broad neutralization activity in simian/human immunodeficiency virus-infected monkeys

Archived longitudinal plasma samples were available only from six macaques. Of these, G1010V, G1015R and G1020R were infected with SHIV1157ipd3N4, whereas G0802V, G0815R and G0821R were infected with SHIVSF162P3. Longitudinal plasmas were available from these animals at various time points: weeks 54–217 for G0802V, G0815R, G0821R and G1010V, but up to 321 weeks for G1015R and G1020R. Baseline plasma samples were available from all six macaques. To determine the plasma neutralization breadth from those six monkeys, we measured their neutralizing activity against a panel of 17 tier 2 viruses (difficult-to-neutralize), two tier 1 viruses (easy-to-neutralize) and autologous viruses (SF162.LS and 1157ipd3N4) (Fig. 2). Autologous nAbs were detectable at week 27 and maintained at high titers throughout the follow-up period in all but G0815R. They also neutralized tier 1 virus MW965.26 as potently as autologous viruses, but neutralized 92RW020.2 less potently. Although nAbs were detected much later in G0815R than in other macaques, the plasma neutralized all four viruses similarly as those from other monkeys by week 217.

Fig. 2

Fig. 2

To determine neutralization breadth and potency of plasma from these monkeys against tier 2 viruses, we performed neutralization assays with 17 tier 2 pseudoviruses that represent multiple subtypes (A, B, C and G), circulating recombinant forms (CRF01, CRF07) and a unique subtype AC recombinant [36–40]. This panel included all 12 viruses in the global panel that was recommended to evaluate the neutralization breadth of anti-HIV-1 sera [39]. Plasmas from weeks 27–54 neutralized only 1–4 viruses (Fig. 2). These low titer neutralization activities were mainly found against 25710 and ZM1197M.PB7. Neutralization activities became more frequently detectable by year 4 (week 217) in three of four monkeys (G0815R, G1015R and G1020R) and the neutralization titers were slightly higher than those from year 1. They neutralized an average of 5.5 (1–8) viruses (Table 1). Plasmas after year 5 (weeks 261–321) were only collected from G1015R and G1020R. They all neutralized more viruses than plasmas from week 217. By week 321, an average of 11.5 (11–12) tier 2 viruses were neutralized. The later plasmas from G1020R had the broadest neutralization spectrum: 14 (83%) and 12 (71%) viruses for plasmas from week 293 and week 321, respectively.

Table 1

Table 1

To determine whether breadth of the neutralization activity significantly increased over time, we ran a mixed-effect GLM on the data from the four monkeys (G0815R, G0821R, G1015R and G1020R) that had three common time points (weeks 27, 54 and 217). We found a strong interaction effect between SHIVs as well as between the subtypes and tier types of the Env-pseudoviruses (P = 8 × 10−5 and 0.0017 on tier 1 and 2 viruses, respectively), indicating that responses were significantly different across different SHIVs, subtypes and tiers. We then restricted our analyses to tier 2 only viruses and found that the magnitude of neutralization responses did not significantly increase at week 54 compared with week 27 (P = 0.21), but they did by week 217 (P = 4.3 × 10−9) even though by only a 50% increase on average. Responses were 1.3 times higher in SHIV1157ipd3N4 compared with SHIVSF162P3. When looking at breadth, the chance of getting positive responses did not statistically significantly change between week 27 and week 54 (P = 0.4), but by week 217 the chance of getting positive responses was over 12-fold higher compared with week 27 (P = 0.015). The chance of getting positive responses in SHIV1157ipd3N4 was 2.7 times higher compared with SHIVSF162P3, but this difference was NS (P = 0.09).

Longitudinal samples were collected from G1015R and G1020R over a time spanning 321 weeks since infection. This allowed us to test whether the breadth of the neutralization activity against tier 2 viruses significantly increased over 6 years of infection. We ran the same model on the two monkeys only, using data from weeks 27, 54, 217, 261, 293 and 321. The chance of getting a positive response at week 217 was significantly higher than at weeks 27 and 54 (P = 0.001 and 0.089, respectively), but equivalent to the chance of getting a positive response at week 261 (P = 0.99). At week 293, there was a 5.5-fold increase in the chance of getting a positive response compared with week 217 (P = 0.012), and at week 321, there was a 4.5-fold increase in the chance of getting a positive response compared with week 217 (P = 0.027). No differences between weeks 293 and 321 were observed. This indicated that the neutralization breadth significantly increased by week 293, but plateaued by week 321 (Fig. 2).

To determine whether antibodies in the plasmas from the two macaques that developed broad neutralization activities could bind the Env glycoprotein of the challenging virus better over time, we measured their binding ability by ELISA. The binding abilities of plasmas to SHIV1157ipd3N4 Env generally increased over time in G1015R (Supplementary Fig. 1A, http://links.lww.com/QAD/B204). However, all plasmas after week 27 in G1020R bound SHIV1157ipd3N4 Env at similar levels, with the exception of the week 321 plasma that showed weaker binding at higher dilutions (Supplementary Fig. 1B, http://links.lww.com/QAD/B204).

Back to Top | Article Outline

Development of distinct neutralization patterns in monkeys infected with the same virus

Both G1015R and G1020R developed broad neutralization activities against 17 tier 2 viruses after 5–6 years of infection (Table 1). However, the neutralization patterns were strikingly different between them (Fig. 2). Plasmas from both macaques at those time points could neutralize seven viruses (CE0217, BJOX2000, CE1176, X2278, 25710, ZM197M.PB7, 16936–2.21 and SC422661.8) similarly and did not neutralize CNE8 and CNE55, except one sample at week 293 from G1020R. Neutralization activities against X1632, CH119, TRO11, 246F3 and 398F1 were developed in G1020R at weeks 293 and 321, but neutralization activities against only X1632 and 398F1 were detected in G1015R at week 321. On the other hand, G1015R developed relatively strong neutralization activity against WITO4160.33 as early as week 54 and CAP45.2.00.G3 at week 217, and nAb titers were maintained at the similar levels throughout the follow-up period. However, G1020R never developed neutralization activity against WITO4160.33 and CAP45.2.00.G3. These distinct neutralization profiles in G1015R and G1020R suggested that different nAbs were elicited even though both macaques were infected by the same virus through the same infection route.

Back to Top | Article Outline

Disparate HIV-1 neutralization breadth among different SHIV-infected monkeys

Single time point plasma samples were available from additional four SHIV1157ipd3N4-infected macaques, four SHIVSF162P3-infected macaques and five SHIVCHN19P4-infected macaques after 6 years of infection. To determine if macaques infected with different SHIVs would also induce similar broad neutralization activity after 6 years of infection, we analyzed plasma samples from those monkeys against the recommended global panel of 12 tier 2 pseudoviruses (Supplementary Fig. 2, http://links.lww.com/QAD/B204). Plasmas from SHIV1157ipd3N4-infected macaques neutralized an average of 6.3 (1–9) viruses (Fig. 3). This was significantly higher than plasmas from SHIVSF162P3-infected macaques or SHIVCHN19P4-infected macaques, which only neutralized 1.4 (0–3) and 1.6 (0–3) viruses on average, respectively (P = 0.017 and P = 0.035, respectively; Student's t test). Significantly, plasmas from four SHIV1157ipd3N4-infected macaques by intrarectally neutralized 7–9 viruses, whereas two SHIV1157ipd3N4-infected macaques by intravenously only neutralized one or three viruses. However, all SHIVSF162P3-infected macaques by intrarectally only neutralize as many as three viruses. These results show that different SHIVs and infection routes can have significant impacts on induction of bnAbs as previously reported [20], and SHIV1157ipd3N4 was superior to SHIVSF162P3 and SHIVCHN19P4 for induction of broad neutralization responses.

Fig. 3

Fig. 3

Back to Top | Article Outline

Determination of specificities of broadly neutralization activities

We next sought to determine neutralization specificities of nAbs in SHIV-infected macaques. As broad neutralization activities were elicited in G015R and G1020R, to determine if three major bnAb epitopes (V2, V3 and CD4bs) were targeted, we mapped their neutralization specificities using two sets of HIV-1 env mutants. Ce1176 could be neutralized by plasmas from both G1015R and G1020R (Fig. 2). Thus, we first determined their neutralization activity against wild type (wt) Ce1176 and five mutants with mutations in V2 (N160K), V3 (N332A) and CD4bs (N279A, N280D and V295N) regions (Fig. 4a and b). Both plasmas could not neutralize N160K and N332A mutants, suggesting that the V2 and V3 regions were targeted by nAbs in both macaques. For three CD4bs mutants, G1015R and G1020R plasmas did not neutralize mutant V295N but more potently neutralized mutant N280D. G1015R and G1020R plasmas neutralized the mutant N279A differently: the G1020R plasma only weakly neutralized mutant N279A, whereas the neutralization titer by G1015R plasma was marginally reduced. These results suggest that nAbs targeting CD4bs were developed in both macaques, but in slightly different manners.

Fig. 4

Fig. 4

CAP45.2.00.G3 was neutralized by only G1015R plasma (Fig. 2). To further confirm the neutralization specificities identified with the Ce1176 mutants, we tested G1015R plasma against a set of 11 CAP45.2.00.G3 mutants [28]. Among six V2 mutants, three (N160A, T162A and K169E) were fully resistant to neutralization by the G1015R plasma (Fig. 4c). Although the R166A and K169V mutants were only slightly more resistant to the G1015R plasma, mutant D167N was more sensitive to the G1015R plasma than the wt virus. The complete resistance of N160K in Ce1176 and N160A in CAP45.2.00.G3 to neutralization by the G1015R plasma confirmed that nAbs targeting the V2 region were present in G1015R. Between two CD4bs mutants which were different from those in Ce1176, mutant T236K was slightly more sensitive to the G1015R plasma than the wt virus, whereas mutant N276D was 44% more resistant than the wt virus. This suggested that CD4bs was likely targeted in G1015R, but not as potently as in G1020R. No significant differences in neutralization susceptibility were observed between gp41 mutants (N616A, N637A and N674A) and the wt virus, suggesting that those sites were not targeted by nAbs in G1015R.

Broad neutralization activities were also detected in G0021R and G0022R (Fig. 3 and Supplementary Fig. 2, http://links.lww.com/QAD/B204). Plasmas from both macaques neutralized Ce1176 but not CAP45.2.00.G3. Thus, we used the Ce1176 mutants to investigate the possible targets of nAbs in both macaques. The G0021R plasma did not neutralize N160K, N280D, V295N and N332A mutants, whereas it more potently neutralized the N279A mutant (Supplementary Fig. 3A, http://links.lww.com/QAD/B204), suggesting that the V2, CD4bs and V3 regions were targeted by nAbs in G0021R, similar to what were observed in G1020R (Fig. 4a). In contrast, the G0022R plasma neutralized all five mutants similarly; the variations in neutralization potency were less than two folds compared with the wt Ce1176 (Supplementary Fig. 3B, http://links.lww.com/QAD/B204). These results suggested that nAbs in G0022R might target epitopes not in the V2, CD4bs and V3 regions.

Back to Top | Article Outline

Discussion

NHPs are the only animal model to evaluate if protective immunity against HIV-1 is elicited by nAb-based vaccines. Thus, understanding if and how bnAbs are elicited during SHIV infection in NHPs can reveal critical clues for the design of more effective vaccines. By studying a group of long-term SHIV-infected macaques, we found that, like in HIV-1-infected humans, SHIV-infected macaques developed broad neutralization activities after years of infection, and that multiple bnAb epitopes in V2, V3 and CD4bs regions were targeted. These findings can have significant implications in design and evaluation of future HIV-1 Env vaccines in NHPs.

Few SHIV-infected NHPs have been maintained for more than 3 years [19–21]. Thus, a group of long-term SHIV-infected NHPs in this study gave us an opportunity to study how broad neutralization activities developed in these monkeys. Broad neutralization activities were rarely detected within 2 years of infection. By year 4, broad neutralization activities were significantly increased. In two monkeys that were followed for 6 years, plasmas neutralized 68% of tier 2 viruses by year 6. These observations demonstrated that, like in HIV-1-infected humans, SHIV-infected NHPs could also develop broad neutralization activities after over 5–6 years of infection. This indicates that bnAbs in SHIV-infected NHPs may also require a lengthy maturation process as in HIV-1-infected humans. As elicitation of bnAbs is most likely required for a successful AIDS vaccine, the key issue for future immunogen design will be to shorten the bnAb maturation time by optimizing the immunization scheme.

Analysis of a group of macaques that were infected for 6 years showed that different SHIVs had various abilities to elicit broad neutralization activities. SHIV1157ipd3N4-infected macaques had significantly broader neutralization activities than SHIVSF162P3-infected or SHIVCHN19P4-infected macaques. Among six SHIV1157ipd3N4-infected macaques, four intrarectally infected macaques had broader neutralization activities than the other two intravenously infected macaques. This is an encouraging observation that given enough time, infection of NHPs by some SHIVs through an appropriate route can likely induce broad neutralization activities. On the contrary, all four macaques infected with SHIVSF162P3 intrarectally did not elicit broad neutralization activities. Infection of five macaques by SHIVCHN19P4 also failed to induce broad neutralization activities. This is in line with the observation in that only low-tier neutralization activity against a tier 1 virus was detected in SHIVDH12-infected macaques after 5 years of infection [20]. Although the number of macaques was relatively small, these results indicate that different SHIV strains and infection routes can have a significant impact on development of bnAbs after infection.

Previous studies showed that broad neutralization activities were only found in a few macaques after screening a large number of monkeys within 1–2 years of infection [19,21]. We found that two out of three SHIV1157ipd3N4-infected macaques were able to develop broad neutralization activities that neutralized at least 65% of tier 2 viruses after 5 years of infection. High viral loads and greater diversity of the env gene sequences may played an important role in development of cross-reactive neutralization in SHIVAD8-infected Rh macaques [33] as well as in infected humans [34,35]. Thus, high viral loads in late stage of infection that allowed viruses to accumulate more mutations may be key for development of broad neutralization activities in both G1015R and G1020R macaques. One study showed that plasmas from some SHIVSF162P3N-infected Rh macaques could broadly neutralize eight tier 2 viruses by 96 weeks post infection [21]. In our study, however, plasmas from SHIVSF162P3-infected macaques only neutralized 1–6 tier 2 viruses. This was probably due to the use of different challenging SHIV strains (SHIVSF162P3N versus SHIVSF162P3) and monkey species (Indian Rh macaques versus Chinese Rh macaques) in two studies [41,42].

Plasmas from G1015R and G1020R showed distinct neutralization profiles with a panel of 17 tier 2 viruses. As both macaques were infected intrarectally with the same SHIV1157ipd3N4 stock, these results suggest that hosts with different genetic backgrounds might have an impact on development of bnAb specificities. Although this observation warrants further validation with more monkeys, this observation may have important implications in future vaccine design.

Potential epitopes targeted by antibodies from macaques with broad neutralization activities was mapped to the gp120 N332 glycan site in one monkey infected with SHIVAD8[19]. In this study, we found that neutralization specificities for three common bnAb epitopes (V2, V3 and CD4bs) were all likely targeted in three SHIV1157ipd3N4-infected macaques (G1015R, G1020R and G0021R). This is very encouraging as bnAbs similar to those targeting V1V2, V3 and CD4bs by human bnAbs are likely elicited by SHIV in NHPs. This raises the hope that a better designed vaccine approach can elicit broad neutralization activities in NHPs. These results demonstrate that SHIV1157ipd3N4-infected Chinese Rh macaques can serve as a proper model to study bnAb maturation.

The number of monkeys in this study is relatively small, and the neutralization breadth was not the initial goal of the study. Thus, only limited blood samples were preserved for analysis neutralization breadth. Therefore, a well designed study with numbers of SHIV1157ipd3N4-infected monkeys better powered to confirm our observations is desirable, as it would help to elucidate mechanisms of bnAb maturation in NHPs. However, two monkeys were still alive after 6 years of infection and blood samples were regularly collected. More importantly, peripheral blood mononuclear cells from both monkeys have been cryopreserved. This will allow us to isolate monoclonal bnAbs from these monkeys to more precisely determine whether the evolution pathways, usages of B cell germlines and specificities of bnAbs in NHPs are similar to those in humans. Knowledge learned from these studies will have important implications for better utilization of NHP models for AIDS vaccine development.

Back to Top | Article Outline

Acknowledgements

We thank David C. Montefiori and Celia C. LaBranche for the global panel of 12 HIV-1 env clones; Penny Moore and Lynn Morris for CAP45.2.00.G3 env mutants; Ruth Ruprecht for NL-LucR.1157ipd3N4 clone; and National Institutes for Food and Drug Control for the tier 1 and 2 env clones.

The current work was supported by the National Natural Science Foundation of China (grant no. 31670162), Program for JLU Science and Technology Innovative Research Team (grant no. 2017TD-05) and CAMS Innovation Fund for Medical Sciences (grant no. 2016-I2M-1–019).

Author contributions: F.G. and X.Y. conceived the study; N.G., W.W., C.W., T.G. and R.G. performed experiments; N.G., W.W., C.W., B.Y., X.Y., C.Q. and F.G. analyzed data; E.E.G. performed statistical analysis; Z.C. generated the SHIV clone; S.T. and S.H. generated the env mutants; N.G., W.W., C.W., X.Y., E.E.G., S.H. and F.G. wrote and edited the article.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

References

1. Doria-Rose NA, Connors M. Antibody-secreting B cells in HIV infection. Curr Opin HIV AIDS 2009; 4:426–430.
2. Sather DN, Stamatatos L. Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. Vaccine 2010; 28 (suppl 2):B8–B12.
3. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 2011; 85:4828–4840.
4. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 2011; 85:11502–11519.
5. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014; 28:163–169.
6. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012; 37:412–425.
7. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 2015; 16:571–576.
8. Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 2016; 533:105–109.
9. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118–122.
10. Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, et al. A mouse model for HIV-1 entry. Proc Natl Acad Sci U S A 2012; 109:15859–15864.
11. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015; 349:aac4223.
12. Bradley T, Fera D, Bhiman J, Eslamizar L, Lu X, Anasti K, et al. Structural constraints of vaccine-induced tier-2 autologous HIV neutralizing antibodies targeting the receptor-binding site. Cell Rep 2016; 14:43–54.
13. Escolano A, Steichen JM, Dosenovic P, Kulp DW, Golijanin J, Sok D, et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 2016; 166:1445–1458.e12.
14. Gray ES, Moody MA, Wibmer CK, Chen X, Marshall D, Amos J, et al. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. J Virol 2011; 85:7719–7729.
15. Lynch RM, Rong R, Boliar S, Sethi A, Li B, Mulenga J, et al. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol 2011; 85:905–915.
16. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7:e1001251.
17. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, Members CCT, et al. The development of CD4 binding site antibodies during HIV-1 infection. J Virol 2012; 86:7588–7595.
18. Kraft Z, Derby NR, McCaffrey RA, Niec R, Blay WM, Haigwood NL, et al. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 2007; 81:6402–6411.
19. Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, Gautam R, et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci U S A 2011; 108:20125–20129.
20. Shingai M, Donau OK, Schmidt SD, Gautam R, Plishka RJ, Buckler-White A, et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Natl Acad Sci U S A 2012; 109:19769–19774.
21. Jia M, Lu H, Markowitz M, Cheng-Mayer C, Wu X. Development of broadly neutralizing antibodies and their mapping by monomeric gp120 in human immunodeficiency virus type 1-infected humans and simian-human immunodeficiency virus SHIVSF162P3N-infected macaques. J Virol 2016; 90:4017–4031.
22. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, et al. Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 2006; 80:8729–8738.
23. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, Blanchard J, et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 2001; 75:1990–1995.
24. Chen Z, Huang Y, Zhao X, Skulsky E, Lin D, Ip J, et al. Enhanced infectivity of an R5-tropic simian/human immunodeficiency virus carrying human immunodeficiency virus type 1 subtype C envelope after serial passages in pig-tailed macaques (Macaca nemestrina). J Virol 2000; 74:6501–6510.
25. Wang W, Cong Z, Jiang H, Chen T, Jin G, Xiong J, et al. Comparison of viral burden and disease progression in Chinese-origin rhesus macaques infected with common experimentally applied chimeric virus: SHIV-1157ipd3N4, SHIV-162P3, or SHIV-KB9. J Med Primatol 2014; 43:247–257.
26. Wang C, Jiang C, Gao N, Zhang K, Liu D, Wang W, et al. Immunologic and virologic mechanisms for partial protection from intravenous challenge by an integration-defective SIV vaccine. Viruses 2017; 9:135.
27. Townsley S, Mohamed Z, Guo W, McKenna J, Cleveland B, LaBranche C, et al. Induction of heterologous tier 2 HIV-1-neutralizing and cross-reactive V1/V2-specific antibodies in rabbits by prime-boost immunization. J Virol 2016; 90:8644–8660.
28. Moore PL, Gray ES, Sheward D, Madiga M, Ranchobe N, Lai Z, et al. Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol 2011; 85:3128–3141.
29. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999; 284:816–819.
30. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw 2015; 67:1–48.
31. Ling B, Veazey RS, Luckay A, Penedo C, Xu K, Lifson JD, et al. SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. AIDS 2002; 16:1489–1496.
32. Del Prete GQ, Lifson JD, Keele BF. Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences. Curr Opin HIV AIDS 2016; 11:546–554.
33. Yamamoto T, Lynch RM, Gautam R, Matus-Nicodemos R, Schmidt SD, Boswell KL, et al. Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. Sci Transl Med 2015; 7:298ra120.
34. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013; 496:469–476.
35. Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014; 509:55–62.
36. Matthews TJ. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 1994; 10:631–632.
37. Moore JP, Burton DR. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med 2004; 10:769–771.
38. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu Rev Immunol 2010; 28:413–444.
39. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2014; 88:2489–2507.
40. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 2010; 84:1439–1452.
41. Ho SH, Tasca S, Shek L, Li A, Gettie A, Blanchard J, et al. Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J Virol 2007; 81:8621–8633.
42. Shakirzyanova M, Tsai L, Ren W, Gettie A, Blanchard J, Cheng-Mayer C. Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N. J Virol 2012; 86:9432–9442.

* These two authors contributed equally to this work.

† These three authors contributed equally to this work.

Keywords:

infection; macaques; maturation; neutralization; simian/human immunodeficiency virus

Supplemental Digital Content

Back to Top | Article Outline
Copyright © 2018 Wolters Kluwer Health, Inc.